Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phenylephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.93 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.93 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.93 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.93 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.93 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.93 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.93 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.93 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.93 |
| ▸ | HTR1A | P08908 | 2/20 | 0.93 |
| ▸ | TSHR | P16473 | 2/20 | 0.93 |
| ▸ | DRD1 | P21728 | 2/20 | 0.93 |
| ▸ | DRD3 | P35462 | 2/20 | 0.93 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.93 |
| ▸ | HTR7 | P34969 | 1/20 | 0.93 |
| ▸ | RAB9A | P51151 | 1/20 | 0.93 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.93 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.90 |
| ▸ | LMNA | P02545 | 3/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylephrine SCHEMBL1650043 | 1.00 | HIF1A (0.93) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL28114309 | 0.98 | HIF1A (0.90) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL4711 | 0.96 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL4712 | 0.96 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL895602 | 0.96 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL29392606 | 0.96 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL29382851 | 0.96 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL29374674 | 0.96 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL3643743 | 0.95 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL10953364 | 0.95 | HIF1A (0.96) | HIF1AADRA2AADRA2BADRA2CADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| US-20240074944-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2024-03-07 | — | — | US | claimed |
| US-20230303305-A1 | METHOD AND PACKAGE FOR REDUCING THE DEGRADATION OF A DRUG AND/OR EXCIPIENT, E.G. POLYSORBATE STABILIZER, IN A PHARMACEUTICAL PRODUCT | OAKTREE FUND ADMINISTRATION, LLC | 2023-09-28 | — | — | US | claimed |
| EP-4247316-A1 | POLYMER VIALS HAVING STANDARD EXTERNAL DIMENSIONS AND REDUCED INTERNAL VOLUME | SiO2 Medical Products, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| US-20230277415-A1 | POLYMER VIALS HAVING STANDARD EXTERNAL DIMENSIONS AND REDUCED INTERNAL VOLUME | SIO2 MEDICAL PRODUCTS, INC. | 2023-09-07 | — | — | US | claimed |
| US-20230263957-A1 | ATOMIC LAYER DEPOSITION COATED PHARMACEUTICAL PACKAGING AND IMPROVED SYRINGES AND VIALS, E.G. FOR LYOPHILIZED/COLD-CHAIN DRUGS/VACCINES | OAKTREE FUND ADMINISTRATION, LLC | 2023-08-24 | — | — | US | claimed |
| US-11724860-B2 | Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus | SIO2 MEDICAL PRODUCTS, INC. (US) | 2023-08-15 | — | — | US | claimed |
| US-11684546-B2 | PECVD coated pharmaceutical packaging | SIO2 MEDICAL PRODUCTS, INC. (US) | 2023-06-27 | — | — | US | claimed |
| CN-102149282-A | Carbonate prodrugs and methods of using the same | NEUROGESX INC | 2011-08-10 | — | — | CN | claimed |
| CN-201791533-U | Activating and recycling device for phenylephrine carrier catalyst | WEIFANG HAPPY PHARMACEUTICAL CO LTD | 2011-04-13 | — | — | CN | claimed |
| CN-201791519-U | Deoxidation adrenergic hydrogenation device | WEIFANG HAPPY PHARMACEUTICAL CO LTD | 2011-04-13 | — | — | CN | claimed |
| EP-2300004-A2 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | Duke University (US) | 2011-03-30 | — | — | EP | claimed |
| CN-101951767-A | Orally disintegrating tablet comprising diphenhydramine | EURAND INC | 2011-01-19 | — | — | CN | claimed |
| CN-101862295-A | Aggregate having enhanced deformability and including at least three amphipatic substances | IDEA AG | 2010-10-20 | — | — | CN | claimed |
| CN-101686681-A | Formulations comprising clopidogrel and sulfoalkyl ether cyclodextrins and methods of use thereof | CYDEX PHARMACEUTICALS INC | 2010-03-31 | — | — | CN | claimed |
| WO-2009140621-A2 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2009-11-19 | — | — | WO | claimed |
| CN-101437478-A | Ocular delivery of polymeric delivery formulations | QLT USA INC (US) | 2009-05-20 | — | — | CN | claimed |
| CN-101351387-A | Continuously sealing one way valve assembly and fluid delivery system formulations for use therein | RESEAL INTERNAT LTD PARTNERSHI (US) | 2009-01-21 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | ADRA1A 1456/4885ADRA1B 1104/4885ADRA1D 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.